Recent News

• 04.24.2025 - Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
• 04.23.2025 - Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
• 04.23.2025 - Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
• 04.15.2025 - Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
• 03.31.2025 - Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• 03.18.2025 - Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
• 03.10.2025 - Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.05.2025 - Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Recent Filings

• 04.16.2025 - S-3 Registration statement under Securities Act of 1933
• 04.16.2025 - S-3 Registration statement under Securities Act of 1933
• 04.14.2025 - D Notice of Exempt Offering of Securities
• 04.03.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.01.2025 - 8-K Current report
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]